Evolent Health (EVH) Misses Q2 EPS by 1c; Offers FY23 Revenue Guidance

Evolent Health (NYSE: EVH) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $469.1 million versus the consensus estimate of $460.68 million.

GUIDANCE:

Evolent Health sees FY2023 revenue of $1.94-1.97 billion, versus the consensus of $1.95 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Tutor Perini launches $400M senior notes offering due 2033